Today, Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority, met with a delegation from AstraZeneca, led by Dr. Hatem El Wardany, President of AstraZeneca’s Board of Directors. The meeting aimed to explore ways to strengthen cooperation in localizing pharmaceutical manufacturing and to discuss incentives for increasing investment in the Egyptian pharmaceutical sector, in a way that contributes to developing the industry and expanding export opportunities to African markets, in line with state efforts to achieve self-sufficiency and enhance competitiveness of the national industry.
During the meeting, the company’s expansion plans in Egypt were reviewed, particularly related to strengthening its localization programs and expanding the production of medicines to meet the needs of the Egyptian market and aid export plans to Africa. Additionally, the meeting addressed the main challenges and opportunities for cooperation with the Egyptian Drug Authority in creating an investment climate that is both stimulating and attractive for international companies in the pharmaceutical sector.
The attendees praised the EDA’s efforts to support the pharmaceutical industry, attract direct foreign investment, and implement flexible policies that align with industry-development requirements, strengthening Egypt’s role as a regional hub for the manufacturing and export of medicines.
The meeting was attended by Counselor Dr. Mohamed El-Demerdash, Vice President of the State Council and Legal Advisor to the EDA; Prof. Dr. Hanan Amin, Head of the Central Administration for Pharmaceutical Products; Dr. Amany Gawdat, Associate to the EDA Chairman and Supervisor of the Central Administration of the Chairman Office Dr. Osama Hatem, Associate Chairman for Policy and International Cooperation & Supervisor of the Central Administration for Drug Policy and Market Access; and Dr. Hamada Gamal Sherif, Associate Chairman for Updating and Developing Pharmaceutical Registration Systems and Head of the General Administration for Pharmaceutical Products Registration.
On AstraZeneca’s side, the meeting was attended by Dr. Mohamed Amin, Member of the Board of Directors for Market Support; Dr. Ahmed Qeshta, Member of the Board of Directors for Government and Corporate Affairs; Mr. Mohamed Gamal, Chief Financial Officer of AstraZeneca; and Mr. Ramy Farid, Legal Affairs Manager for AstraZeneca.
This meeting comes as part of the Egyptian Drug Authority’s ongoing efforts to develop its pharmaceutical policy framework and foster strategic partnerships with major international companies, reflecting positively on improving the quality of health care for Egyptian citizens and ensuring the availability of innovative medicines that meet the highest international standards.